Author

M. Rutkowska

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 5 Assay:proteomics· 4 Organism:human· 3 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

F. Schmidt· 5 shared T. Hatziioannou· 5 shared Y. Weisblum· 5 shared A. Cho· 4 shared C. Gaebler· 4 shared M. Caskey· 4 shared P. D. Bieniasz· 4 shared A. Gazumyan· 3 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

F. Schmidt

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis.

T. Kehrer, A. Cupic, C. Ye, S. Yildiz, M. Bouhhadou, N. A. Crossland, E. Barrall, P. Cohen, A. Tseng, T. Cagatay, R. Rathnasinghe, D. Flores, S. Jangra, F. Alam, N. Mena, , L. Miorin

This study shows SARS-CoV-2 ORF6 disrupts nucleo-cytoplasmic trafficking, inhibits IFN signaling, and modulates viral protein expression, with variant polymorphisms affecting its function.

bioRxiv · Oct 18, 2022Microbiology

High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies

F. Schmidt, Y. Weisblum, M. Rutkowska, D. Poston, J. Da Silva, F. Zhang, E. Bednarski, A. Cho, D. Schaefer-Babajew, C. Gaebler, M. Caskey, M. C. Nussenzweig, T. Hatziioannou, P. D. Bieniasz

This study shows that multiple neutralizing epitopes in SARS-CoV-2 spike proteins are targeted by polyclonal antibodies, and 20 mutations can confer resistance, but vaccinated and infected individuals' plasma neutralizes these resistant variants and diverse sarbecoviruses.

bioRxiv · Aug 6, 2021Microbiology

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2

F. D. Mast, P. C. Fridy, N. E. Ketaren, J. Wang, E. Y. Jacobs, J. P. Olivier, T. Sanyal, K. R. Molloy, F. Schmidt, M. Rutkowska, Y. Weisblum, L. M. Rich, E. R. Vanderwall, N. Dambrauskas, V. Vigdorovich, , M. P. Rout

This paper presents a large repertoire of high-affinity nanobodies against SARS-CoV-2 Spike protein with potent neutralization properties and resistance to viral variants.

bioRxiv · Apr 8, 2021Biochemistry

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

F. Muecksch, Y. Weisblum, C. Barnes, F. Schmidt, D. Schaefer-Babajew, J. Lorenzi, A. Flyak, A. DeLaitsch, K. Huey-Tubman, S. Hou, C. Schiffer, C. Gaebler, Z. Wang, J. Da Silva, D. Poston, , P. Bieniasz

This study examines how somatic mutations in SARS-CoV-2 antibodies affect their neutralization potency, breadth, and resistance to escape mutations across six antibody lineages.

bioRxiv · Mar 7, 2021 · PreprintMicrobiology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, , P. D. Bieniasz

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.

bioRxiv · Jul 21, 2020Microbiology

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

F. Schmidt, Y. Weisblum, F. Muecksch, H.-H. Hoffmann, E. Michailidis, J. C. C. Lorenzi, P. Mendoza, M. Rutkowska, E. Bednarski, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, M. Cipolla, , P. D. Bieniasz

The paper describes assays using pseudotyped and chimeric viruses to measure SARS-CoV-2 neutralizing antibody activity, showing correlation with authentic assays.

bioRxiv · Jun 8, 2020Microbiology